checkAd
    Startseite > Aktien > BridgeBio Pharma > Nachrichten
    BridgeBio Pharma Aktie
    25,81
     
    EUR
    -3,08 %
    -0,82 EUR
    Letzter Kurs 31.05.24 Tradegate
    25,64
     
    EUR
    200 STK
    Geldkurs 31.05.24
    25,96
     
    EUR
    200 STK
    Briefkurs 31.05.24
    ISIN: US10806X1028 · WKN: A2PLX7 · SYM: 2CL · USA

    Neueste Nachrichten

    Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    29.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
    24.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    15.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
    14.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensit
    13.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
    02.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
    02.05.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    10.04.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
    07.04.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
    20.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
    06.03.24 · globenewswire · BridgeBio Pharma
    BridgeBio Pharma Announces Proposed Public Offering of Common Stock
    04.03.24 · globenewswire · BridgeBio Pharma